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Abstract
Background—IL-9 is important for the growth and survival of mast cells. IL-9 is produced by T 
cells, NKT cells, mast cells, eosinophils, and innate lymphoid cells, although the cells required for 
mast cell accumulation during allergic inflammation remain undefined.
Objective—To elucidate the role of Th9 cells in promoting mast cell accumulation in models of 
allergic lung inflammation.
Methods—Adoptive transfer of OVA-specific Th2 and Th9 cells was used to assess the ability of 
each subset to mediate mast cell accumulation in tissues. Mast cell accumulation was assessed in 
wild type mice and mice with PU.1-deficient T cells subjected to acute and chronic models of 
allergic inflammation.
Results—Adoptive transfer experiments demonstrated that recipients of Th9 cells had 
significantly higher mast cell accumulation and expression of mast cell proteases as compared to 
control or Th2 recipients. Mast cell accumulation was dependent on IL-9, but not IL-13, cytokine 
required for many aspects of allergic inflammation. In models of acute and chronic allergic 
inflammation, decreased IL-9 levels in mice with PU.1-deficient T cells corresponded to 
diminished tissue mast cell numbers and expression of mast cell proteases. Mice with PU.1-
deficient T cells have defects in IL-9 production from CD4+ T cells, but not NKT cells or innate 
lymphoid cells, suggesting a T helper cell-dependent phenotype. Rag1−/− mice subjected to a 
chronic model of allergic inflammation displayed reduced mast cell infiltration comparable to 
accumulation in mice with PU.1-deficient T cells, emphasizing the importance of IL-9 produced 
by T cells in mast cell recruitment.
Conclusion—Th9 cells are a major source of IL-9 in models of allergic inflammation and play 
an important role in mast cell accumulation and activation.
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INTRODUCTION
IL-9, originally considered a Th2-cytokine, is now ascribed to a specialized subset of CD4+ 
T helper cells, the Th9 subset (1, 2). IL-9 plays an important role in human and murine 
atopic disease (3–5), anti-tumor immunity (6), anaphylaxis to allergen challenge at mucosal 
surfaces (7), immunity to intestinal parasites (8, 9), antiviral immunity (10) and autoimmune 
inflammation (11, 12). IL-9 is a pleiotropic cytokine with direct and indirect effects on 
multiple cell types. IL-9 acts as a growth factor for T cells (13, 14), enhances the production 
of IgE from B cells (15), induces mucus production by epithelial cells (16, 17) and promotes 
the proliferation and differentiation of mast cells (18, 19). In mast cells, IL-9 enhances 
expression of MC proteases, increases expression of the high-affinity IgE receptor 
(FcεR1α), and induces IL-6 production (18–20). Transgenic expression of IL-9 in the lungs 
of mice results in mast cell hyperplasia, and studies with IL-9-deficient mice demonstrated a 
role for IL-9 in pulmonary mastocytosis (21). In allergic airway inflammation, mast cells are 
increased in both the acute and chronic models of disease (22–24). Mast cell accumulation is 
a critical aspect of the pathology of immediate hypersensitivity responses (25).
IL-9 is mainly produced by T cells but can also be produced by mast cells (26), NKT cells 
(27), eosinophils (28) and type 2 innate lymphoid cells (ILC2s) (29). The transcription 
factors important for Th9 lineage determination and IL-9 regulation include IRF4, BATF 
and the ETS family transcription factor, PU.1 (5, 30, 31). Increased PU.1 expression leads to 
a decrease in Th2 cytokines and increased phenotypic characteristics of Th9 cells including 
production of IL-9. Mice with a T-cell specific deletion of PU.1 have decreased IL-9 in vivo 
and do not develop allergic inflammation despite the presence of normal Th2 and Th17 
responses. Recent studies with Il9 fate reporter mice that evaluated the IL-9-producing cell 
types established innate lymphoid cells (ILCs) as a major source of IL-9 in an in vivo model 
of lung inflammation (29). Thus, the functional relevance for Th9 cells specifically in mast 
cell accumulation and the relative role of cell types that produce IL-9 in allergic 
inflammation need further investigation.
We hypothesized that Th9 cells play an important role in mast cell recruitment and 
activation in acute and chronic models of allergic inflammation. In this report, we evaluated 
the effects of Th9 cells on mast cell recruitment in adoptive transfer experiments and models 
of acute and chronic allergic inflammation. We demonstrate that Th9 cells are an important 
source of IL-9 and promote mast cell accumulation through IL-9-dependent mechanisms in 
vivo.
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METHODS
Mice
BALB/c, Rag1−/− and DO11.10 TCR transgenic mice were purchased from Jackson 
Laboratories. Female C57BL/6 mice were purchased from Harlan Bioscience. Mice with 
conditional deletion of the gene encoding PU.1 (Sfpi1fl/fl) on the C57BL/6 background have 
been described (32) and were mated to mice carrying a transgene encoding Cre recombinase 
under control of the Lck promoter (B6(CBA)-Tg(Lck-cre)I540Jxm/J). Mice were maintained 
in pathogen-free conditions and all studies were approved by the Animal Care and Use 
Committee of the Indiana University School of Medicine.
Adoptive Transfer Experiments and Cytokine Neutralization
Briefly, differentiated OVA-specific Th2 or Th9 cells were adoptively transferred 
intravenously into wild-type recipient mice (33). Twenty-four hours after cell transfer, mice 
were challenged intranasally with 100 μg OVA plus 500 ng TSLP for 5 days. Mice were 
then sacrificed 24 h after the last challenge for further analysis. To neutralize cytokine in 
recipients of Th2 or Th9 cells, we injected mice via tail vein with anti-IL-9 (10 μg/dose), 
anti-IL-13 (10 μg/dose), or IgG2b control Ab (10 μg/dose, R&D Systems) on days 1, 3, and 
5.
Induction of Allergic inflammation
Acute Model: Wild type (WT) and Sfpi1lck−/− mice were sensitized by intraperitoneal 
injection of OVA (Sigma) adsorbed with alum (Sigma) on days 0 and 7 and subsequently 
challenged with intranasal OVA for 5 days as described previously (5). Where specified, 
mice were given 20 μg control antibody or anti-IL-9 (222622; R&D Systems) intravenously 
30 min before the first, third and fifth challenges. Mice were sacrificed 48 h after the final 
intranasal challenge. Chronic model: WT and Sfpi1lck−/− mice were sensitized by intranasal 
injection of 40 μg HDM extract (Dermatophagoides pteronyssinus in phosphate-buffered 
saline, PBS) from Greer Laboratories (Lenoir, NC) or PBS 3 days per week for 5 weeks. 
Mice were sacrificed 24 h after the final intranasal challenge. Cells from mediastinal lymph 
nodes were stimulated with HDM for 5 days, and cytokine production measured by ELISA.
Bronchoalveolar lavage and lung histology
The trachea was cannulated and lungs were lavaged three times with 1 ml PBS to collect 
bronchoalveolar lavage (BAL) cells. Cells recovered in BAL fluid were counted with a 
hemocytometer. Eosinophils, neutrophils, T cells, B cells and mononuclear cells in the BAL 
fluid were distinguished by cell size and by expression of CD3, B220, CCR3, CD11c and 
major histocompatibility complex class II and analyzed by flow cytometry as described (34).
Cytokine concentrations in cell-free BAL fluid were measured with Multiplex reagents 
(Millipore).
After the lavage, lung tissues were fixed in neutral buffered Formalin. Paraffin-embedded 
lung tissue sections were stained with hematoxylin and eosin (H & E), Periodic Acid-Schiff 
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(PAS) or toluidine blue to evaluate the infiltration of inflammatory cells, mucus-producing 
cells and mast cells, respectively, by light microscopy.
Intracellular cytokine staining (ICS)
BAL cells were stimulated with PMA and ionomycin for 5 h with the addition of monensin 
during the last 3h of stimulation for cytokine analysis by intracellular cytokine staining 
(ICS). Cells were stained for surface CD4, fixed with 4% neutral buffered paraformaldehyde 
and permeabilized with saponin. Cells were then stained with fluorochrome-conjugated anti-
mouse IL-9 and anti-IL-4. Before transfer, a sample of Th2 and Th9 cultures were activated 
with PMA/ionomycin and stained with fluorochrome-conjugated anti-mouse IL-9, IL-13, 
CD4, and KJ1.26 (eBioscience).
Intranasal administration of IL-33 and culture of ILCs
WT C57BL/6 and Sfpi1lck−/− mice were challenged intranasally with 500 ng recombinant 
mouse IL-33 (Biolegend) on days 0, 1 and 2. Control mice received PBS only. Mice were 
sacrificed on day 3 and BAL cells were isolated for analysis. Briefly, ILCs were sorted by 
gating on the lin− Thy1+ and CD4− cell population. CD4+ T cells were identified as 
Thy1+CD4+. Sorted ILCs and CD4+ cells were cultured for 24h in 96 well plates 
(concentration of 5×103 cells/30 μl) with IL-2 (100 U/ml) and IL-9 expression determined 
by quantitative RT-PCR.
Alpha galactosylceramide administration
WT C57BL/6 and Sfpi1lck−/− mice were challenged intranasally with 2 μg alpha 
galactosylceramide or PBS and 24 h after challenge the expression of cytokines were 
determined in the lung tissues by quantitative RT-PCR.
Quantitative RT-PCR
Lung tissues were homogenized in a tissue lyser (Qiagen) and RNA isolated with an RNeasy 
kit (Qiagen) was used for synthesis of cDNA for subsequent analysis. Quantitative PCR was 
performed with Taqman Fast Universal PCR Master Mix and commercially available 
primers for genes Mcpt1, Mcpt2, Il9, Ifng, Muc5ac, and Clca3 with the 7500 Fast Real-Time 
PCR system (Applied Biosystems, Foster City, CA). RNA was normalized to expression 
levels of β2-microglobulin and relative expression was calculated by the change-in-threshold 
(−ΔΔ CT) method.
Mouse MCPT-1 (mMCP-1) in serum
mMCP-1 is a mouse mast cell protease that can be detected in the serum of mice after 
activation of mast cells (35). Mouse mast cell protease-1 kit was purchased from 
eBioscience and used according to the manufacturer’s protocol.
Immunohistochemistry
Sections were deparaffinized with xylene and rehydrated from ethanol to water. Antigen 
retrieval was performed by high pH antigen retrieval using the proprietary DAKO buffer in 
the DAKO PT Link. Endogenous peroxidase activity was quenched by incubating the 
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specimen for 10 minutes with 3% hydrogen peroxide. Tissue sections were incubated with 
primary antibodies recognizing CD3 (DAKO, IR 503) and CD117 (c-kit, Santa Cruz, 
sc-168) for 30 minutes. C-KIT staining was detected with LSAB2 (DAKO; HRP labeled 
streptavidin followed by donkey -anti–goat-biotin) and DAB, CD3 staining followed by 
Rabbit-on-mouse-AP (Biocare) with Vulcan Red, and sections were counterstained with 
hematoxylin (DAKO).
RESULTS
Transfer of Th9 cells increased the activation of mast cells and their accumulation
To compare the ability of Th9 and Th2 cells to promote mast cell accumulation in situ, a 
hallmark of allergic inflammation, we adoptively transferred differentiated DO11.10 Th9 or 
Th2 cells to BALB/c mice followed by intranasal allergen (OVA+TSLP) challenge of the 
recipient mice as recent studies from our laboratory have shown that TSLP results in 
enhanced Th9-mediated pathology, compared to mice given OVA alone (33). Before 
transfer, we assessed the polarization of differentiated Th2 (high IL-13, low IL-9) and Th9 
(high IL-9, low IL-13) cells by intracellular staining and observed patterns of cytokine 
secretion (Fig 1, A) similar to our previous report (33). Recipients of Th2 or Th9 cells 
demonstrated similar inflammatory cell infiltration in the bronchoalveolar fluid (BAL) that 
was predominantly eosinophilic (Fig 1, B). There was a trend toward increased 
inflammation in recipients of Th9 cells and this was similar to our previous report (33). 
Mucus production, assessed by histological analyses of lung tissues (Fig 1, C) or expression 
of genes associated with mucus metaplasia (Fig 1, D) was indistinguishable between 
recipients of Th2 and Th9 cells. The effects of Th2 and Th9 cells on mast cell accumulation/
activation indicate that although Th2 cells modestly increased mast cell numbers and mast 
cell protease expression, Th9 cells were significantly more potent in increasing mast cell 
numbers and the expression of mast cell proteases (Fig 1, E). The increased expression of 
the mast cell proteases is likely due to both increased numbers of mast cells, and increased 
gene expression per cell. Thus, Th9 cells have a significantly greater ability to promote mast 
cell accumulation during allergic inflammation.
To determine if mast cell accumulation following adoptive transfer of Th9 cells required 
IL-9, Th9 cells were transferred into BALB/c mice and the recipient mice challenged 
intranasally with allergen for 5 days. Before the first, third, and fifth challenge, mice 
received anti-IL-9, anti-IL-13 or control antibody. Th9 cell recipient mice that received 
neutralizing anti-IL-9 had significantly reduced infiltration of mast cells in tracheal sections 
concomitant with reduced mast cell protease expression as compared to the mice given 
control antibody (Fig 1, F and G). In contrast, blocking IL-13, which diminishes airway 
inflammation (33) did not affect mast cell accumulation or activation (Fig 1, F and G). 
These data indicate that Th9 cells are more efficient than Th2 cells in orchestrating mast cell 
accumulation and inducing mast cell gene expression in vivo.
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Decreased IL-9 corresponds to reduced mast cell numbers in mice with PU.1-deficient T 
cells in an acute model of allergic airway inflammation
To determine if mast cell accumulation in mice subjected to the OVA/Alum protocol for the 
development of acute allergic inflammation is dependent on IL-9, we administered anti-IL-9 
before the first, third, and fifth challenge (5). As shown in Fig 2A, neutralizing IL-9 
dramatically reduced the numbers of infiltrating mast cells in WT mice. We previously 
demonstrated that mice with PU.1-deficient T cells (Sfpi1fl/fl Lck-Cre mice, hereafter 
referred to as Sfpi1lck−/− mice) subjected to an OVA/Alum protocol have significantly lower 
inflammation (total and eosinophil cell counts) that corresponded to lower amounts of IL-9, 
compared to WT mice (5). To determine if diminished IL-9 levels correlate with decreased 
mast cell numbers, we examined mast cell infiltration in Sfpi1lck−/− mice sensitized and 
challenged with OVA. Diminished IL-9 in Sfpi1lck−/− mice (5) corresponded to reduced 
mast cell numbers and decreased expression of mast cell proteases (Fig 2, B and C). These 
studies suggest that Th9 cells mediate mast cell accumulation in an acute model of allergic 
inflammation.
Reduced mast cell numbers in mice with PU.1-deficient T cells correlate with less IL-9 in a 
chronic house dust mite model of allergic pulmonary inflammation
Having shown that IL-9 is required for mast cell accumulation in an acute model of allergic 
inflammation we next examined its role in a house dust mite (HDM) model of chronic 
allergic inflammation without adjuvant. WT and Sfpi1lck−/− mice were challenged 
intranasally with HDM extract for 5 weeks and the development of pulmonary inflammation 
was examined. Consistent with our results for the OVA-induced acute model, inflammation 
in the lungs of Sfpi1lck−/− mice was lower than WT mice (Fig 3, A). Moreover, the cellular 
composition of BAL revealed significantly reduced numbers of eosinophils, neutrophils and 
T cells in PU.1-deficient mice (Fig 3, B). Analysis of cytokine responses indicated that 
approximately 10 % of BAL CD4+ T cells in WT mice stained positive for IL-9 in contrast 
to 0.1% positive cells in Sfpi1lck−/− mice (Fig 3, C). Similarly, IL-4 positive BAL cells were 
decreased in Sfpi1lck−/− mice (Fig 3, C). We next assessed the generation of helper T cell 
responses in the lung draining lymph nodes by stimulating mediastinal lymph node cells 
with HDM extract. We observed that IL-9 production was significantly reduced in cultures 
from Sfpi1lck−/− mice compared with those from control mice, although there was no 
difference in the production of IL-4 (Fig 3, D). These results suggest that in the chronic 
HDM model, inflammation in Sfpi1lck−/− mice is also dependent on IL-9 as there were 
reduced Th9 responses in the draining lymph nodes and BAL, consistent with our earlier 
studies (7). We then assessed mast cell accumulation in situ. Mast cell numbers in tracheal 
sections of PU.1-deficient mice were also reduced concomitant with decreased expression of 
mast cell proteases compared to WT mice (Fig 3, E and F). To determine if T cells and mast 
cells co-localize in the tracheal sections, we performed immunohistochemistry using CD3 
and c-kit antibodies on paraffin embedded sections from the chronic HDM model. We 
observed that T cells and mast cells are present in tracheal sections, but were not located 
directly adjacent to each other (Fig 3, G). Thus, these data indicate that decreased IL-9 
production in mice with PU.1-deficient T cells parallels reduced mast cell numbers/ and 
mast cell protease expression in a chronic airway inflammation model.
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CD4+ T cells are a major source of IL-9 in vivo in a model of allergic pulmonary 
inflammation
IL-9 can be produced by a number of cell types. Although CD4+ T cells from Sfpi1lck−/− 
mice have decreased IL-9 production, it is not known whether T helper cells are the only 
cells affected by Lck-Cre-dependent PU.1-deficiency, and this is an important point in being 
able to link the defects in mast accumulation in Sfpi1lck−/− mice specifically to Th9 cells. As 
NKT cells are also reported to produce IL-9 in vivo (27), we examined the effect of alpha-
galactosylceramide instillation in Sfpi1lck−/− mice. As shown in Supplementary Fig E1A, 
expression of IL-9 and IFN-γ were unimpaired in mice with PU.1 deficiency in T cells 
indicating that PU.1 is not required for the production of IL-9 in NKT cells.
Studies from IL-9 fate reporter mice established ILCs as major producers of IL-9 in an in 
vivo model of papain- and IL-33-induced lung inflammation (29). To determine if ILC 
production of IL-9 is affected by Lck-Cre mediated deletion of PU.1, we intranasally 
challenged WT and Sfpi1lck−/− mice with IL-33 on days 0, 1 and 2. One day after the last 
challenge, populations of ILCs and CD4+ T cells were sorted as described in Materials & 
Methods. After stimulation with IL-2, we observed that PU.1-deficient CD4+ T cells had 
reduced IL-9 expression, compared with control cells, but that IL-9 expression by ILCs was 
not decreased (Supplementary Fig E1B). Thus our data indicate that Lck-Cre-mediated 
deletion of PU.1 affects IL-9 production primarily in conventional CD4+ T cells.
Knowing that ILC production of IL-9 is not affected in Sfpi1lck−/− mice and that ILCs are an 
important source of IL-9, we wanted to test the relative role of Th9 cells and ILCs in mast 
cell accumulation in a chronic HDM induced allergic inflammation model. For these studies 
we compared WT and Sfpi1lck−/− mice to Rag1−/− mice that lack T and B cells but have no 
defect in ILCs (29). Quantification of inflammatory cells in BAL revealed a drastic 
reduction in cell numbers in Rag1−/− mice in comparison to WT or Sfpi1lck−/− mice, 
supporting a requirement for T cells in maximal inflammation in this model (Fig 4, A). 
Analysis indicated a similar and significant reduction of mast cell numbers in the tracheal 
sections of Sfpi1lck−/− and Rag1−/− mice compared to WT mice (Fig 4, B and C). In 
accordance with decreased numbers of mast cells, serum levels of mast cell protease 1 were 
also decreased in Rag1−/− and Sfpi1lck−/− mice, compared to WT mice (Fig 4, D). Thus, 
although Rag1−/− mice had dramatically reduced overall inflammation, the reduction in 
mast cell accumulation is similar to that observed in mice with PU.1-deficient T cells, but 
greater than unchallenged mice. These data suggest although ILCs clearly contribute some 
IL-9 to promote mast cell accumulation, Th9 cells have an obligate role in mast cell 
accumulation during the development of allergic inflammation.
DISCUSSION
Previous studies to define a relevant function for Th9 cells in vivo have utilized IL-9- or 
IL-9R-deficient mice or neutralizing IL-9 antibodies (1, 36). Recent reports with models of 
allergic inflammation and helminthic parasite infection have shown that IL-9 can be 
produced not only by IL-9-producing CD4+ T cells but also by other cells including, ILCs 
(29, 37). Therefore, studies blocking cytokine or cytokine receptor function do not 
definitively link IL-9 function to Th9 function in vivo. To evaluate the biological source of 
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IL-9 in vivo, we employed mice with a conditional deficiency of PU.1 in T cells. We have 
previously shown that these mice have diminished lung inflammation and decreased IL-9 in 
the lung with no impairment of peripheral Th2/Th17/Th1 responses (5, 38). In this report, 
we identified Th9 cells as a major source of IL-9 in the context of allergic pulmonary 
inflammation in mice and demonstrated their ability to induce mast cell accumulation and 
activation.
Our demonstration that adoptive transfer of polarized Th9 cells promotes mast cell 
accumulation, is similar to a previous report showing mast cell accumulation following 
adoptive transfer of HDM-sensitized and polarized Th9 cells (39), and that transfer of Th9 
cells caused rapid worm expulsion and increased numbers of mast cells (37, 40). However, 
our data carries those observations further by showing that Th9 cells are more potent than 
Th2 cells in promoting mast cell accumulation and mast cell gene expression. This is a 
critical point as IL-4 was previously demonstrated to have some compensatory effects on 
mastocytosis in the absence of IL-9 (40). We further demonstrated that IL-9 was required for 
Th9 cells to mediate mast cell accumulation, whereas IL-13 was not required. This is in 
contrast to the ability of Th9 cells to mediate eosinophilic inflammation, where blockade of 
either IL-9 or IL-13 diminished allergic inflammation (33). Thus, mast cell accumulation 
during allergic inflammation might be a specific outcome of Th9- and IL-9-induced 
inflammation.
IL-9 has been reported to regulate mast cell numbers in the lung during chronic allergic 
inflammation (22). However, the cellular source of IL-9 that contributes to this regulation is 
still unclear, and ILCs are a significant source of IL-9 in parasitic infections and some 
models of allergic inflammation (29, 37, 41). We took the approach of examining mast cell 
accumulation in mice that have diminished IL-9 production specifically in Th9 cells 
following deletion of PU.1. Critical for drawing conclusions from this system was 
demonstrating that conditional deletion of PU.1 by an Lck-Cre transgene did not affect IL-9 
production in NKT cells or in ILCs. As we observed normal induction of IL-9 in alpha 
galactosylceramide challenged mice and normal IL-9 production from ILCs in IL-33 
challenged mice, it strongly suggests that the effects of Lck-Cre-dependent PU.1-deficiency 
on IL-9 production are restricted to conventional T cells. NKT cells were linked to 
regulation of mast cell precursors (MCp) in one model of allergic airway disease through an 
IL-9-dependent mechanism, although transgenic IL-9 expression in the intestine did not 
induce alterations in MCp populations (27, 42). Whether Th9 cells also impact MCp 
requires further investigation. Our observations correlate decreased IL-9 in the lungs of mice 
with PU.1-deficient T cells with diminished mast cell recruitment and activation in both the 
acute and chronic models of allergic inflammation suggesting a major contribution of Th9 
cells to this process.
Our report, in combination with other recent work, suggests that Th9 cells, as a source of 
IL-9, are both necessary and sufficient for mast cell accumulation. Adoptive transfer of Th9 
cells in wild type or IL-9-deficient recipients results in increased mast cell accumulation in 
the context of allergen-induced inflammation or parasite infection (37, 39). We further 
demonstrated that Th9 cells are more potent than Th2 cells in mediating this function. We 
show that in mice lacking PU.1 expression in T cells there is decreased tracheal mast cell 
Sehra et al. Page 8
J Allergy Clin Immunol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
accumulation in both acute and chronic inflammation models, consistent with the 
accumulation of tracheal mast cells in IL-9 transgenic mice (43). Moreover, the decrease in 
mast cell numbers in the chronic model in the absence of Th9 cells is similar to that 
observed in Rag1−/− mice that lack T cells but have normal ILC development (29). Thus, 
PU.1-dependent regulation of IL-9 is critical for the ability of T cells to mediate mast cell 
accumulation.
It is not clear if Th9 cells and mast cells need to physically interact during the development 
of allergic inflammation and co-localization has not been examined in detail. In the stroma 
of the lung, it is likely that T cells and mast cells can interact, and some studies have 
supported a role for mast cells as antigen presenting cells (44). However, IL-9 can have both 
local and regional effects by virtue of its release into the microenvironment. We analyzed 
tracheal sections of mice sensitized and challenged with HDM extract, and observed the 
presence but not the co-localization of T cells and mast cells. This result does not exclude 
the possibility that T cells interact directly with mast cells, but it does suggest that T cells 
are not required at the site of mast cell accumulation.
IL-9 is pleiotropic and has many functions in vivo. Among the more recently identified 
functions, studies have demonstrated that IL-9 is an amplifier of ILC2 function and survival 
and IL-9R-deficient mice have reduced numbers of ILC2s in a helminth infection model 
(41). However, we did not observe a decrease in the ILC2 numbers in mice with a 
conditional deletion of PU.1 in T cells (data not shown). This would suggest that the pro-
survival function of IL-9 on ILCs may be autocrine, or at least that Th9 cells do not 
contribute to this activity. We further tested whether ILCs were required for Th9-induced 
mast cell accumulation using an anti-CD25 depleting antibody in the adoptive transfer 
recipients and observed no differences in mast cell accumulation between control antibody 
or anti-CD25 injected mice (data not shown). However, as the depleting antibody also had 
effects on adoptively transferred effector cells, these studies have several caveats in their 
interpretation.
Although mast cells are necessary for immediate hypersensitivity responses, their role in 
mouse models of allergic inflammation is less clear. Allergic lung inflammation can develop 
through at least two mechanisms requiring eosinophils or mast cells, with a role for the latter 
being more apparent for adjuvant-independent models (24, 45–48). However, the 
requirement for mast cells has not been carefully reported in all models examined, might be 
restricted to specific functions, and vary with the genetic background of the mice (24, 49–
51). Indeed, in one model, mast cell accumulation was observed to be IL-9-independent 
(50). Despite the lack of an absolute requirement for mast cells in the development of 
inflammation, these models still display accumulation of mast cells that can be used to 
define the molecular mechanisms of this process.
Th9 cells likely have many functions in the development of allergic inflammation. Although 
they clearly have a role in mast cell accumulation, Th9 cells promote allergic inflammation 
in models that are not strictly mast cell-dependent (47). One of the important remaining 
questions is distinguishing the functions of Th9 cells from those of Th2 cells, which have 
similar and somewhat overlapping roles in promoting allergic inflammation. This report 
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demonstrates that at least one function that is preferentially associated with Th9 cells is 
accumulation of mast cells in situ, and in allergic individuals this might be a critical step 
facilitating type I hypersensitivities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations used
BAL Bronchoalveolar lavage
H & E hematoxylin and eosin
HDM House dust mite
ILC2s Type 2 innate lymphoid cells
ILCs Innate lymphoid cells
mMCP-1 mouse mast cell protease 1
OVA ovalbumin
PAS periodic acid-schiff
PMA Phorbol 12-myristate 13-acetate
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Clinical Implications
Mast cell accumulation in tissues is required for immediate hypersensitivity. This report 
suggests that targeting IL-9 or Th9 cells might be an effective approach for limiting mast 
cell-dependent immunity.
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Figure 1. 
Adoptive transfer of Th9 cells increases mast cell numbers. A, Naive CD4+ T cells from 
DO11.10 mice were differentiated under Th9 / Th2 conditions with OVA323–339 peptide and 
mitomycin C treated antigen presenting cells. Before transfer, the percentage of IL-13+ and 
IL-9+ cells were measured in Th9 / Th2 cell cultures by intracellular cytokine staining. B, 
Total number of inflammatory cells were determined in BAL fluid and numbers of 
eosinophils determined by flow cytometry. C and D, Mucus production was assessed in the 
lung tissues by PAS staining and expression of mucus genes Muc5ac and Clca3 quantified 
by qPCR. E, PBS, Th2 or Th9 DO11.10 cells were intravenously transferred to BALB/c 
mice that were subsequently challenged with OVA+TSLP for 5 days. Mast cells were 
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counted after staining tracheal sections with toluidine blue and expression of mast cell 
proteases was measured in lung tissues by quantitative PCR. F and G, Th9 cell recipients 
received 10 μg of anti-IL-9, anti-IL-13, or IgG2b control mAb on days 1, 3 and 5 before 
challenge with OVA+TSLP. Mice were sacrificed 24 h after the last challenge and mast cell 
numbers were quantitated in tracheal tissue sections by toluidine blue staining and 
expression of mast cell proteases was determined by quantitative PCR. Boxes on low 
magnification micrographs indicate the region for the higher magnification panel. Arrow: 
mast cells. Data are the mean ± SEM of 3–5 mice per group and representative of 2 
independent experiments with similar results. *p < 0.05.
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Figure 2. 
Th9-dependent accumulation of mast cells in an acute model of allergic inflammation. A, 
Wild-type mice were sensitized and challenged using the OVA/alum protocol. Mice 
received control immunoglobulin (control Ab) or anti-IL-9, 30 min before the first, third and 
fifth intranasal challenge. Mice were sacrificed 48 h after the last challenge and tracheal 
tissues were evaluated for the presence of mast cells. B and C, Wild-type and Sfpi1lck−/− 
mice were sensitized and challenged with the OVA/Alum protocol and mast cells were 
counted in toluidine blue stained tracheal tissue sections and quantitative PCR was 
performed for mast cell protease gene expression in lung tissues. Data shown represent the 
mean ± SEM of 5 to 6 mice per group from 2 independent experiments with similar results. 
*p < 0.05.
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Figure 3. 
Th9-dependent accumulation of mast cells in an HDM-induced chronic model of allergic 
inflammation. A–F, Wild-type mice were immunized intranasally with HDM for 5 weeks 
and A, Cellular infiltration in the lungs of wild-type and Sfpi1lck−/− mice was evaluated by 
hematoxylin and eosin (H&E) staining. Magnification is indicated. B, Inflammatory cells in 
the BAL fluid (T cells, B cells, Eosinophils (Eos), Neutrophils (Neu), Dendritic cells (DC) 
and Macrophages (Mac) were evaluated by flow cytometry. C, BAL CD4+ T cells were 
stimulated with PMA and ionomycin for 5 hours to assess cytokine production by 
intracellular staining. D, Cells from mediastinal lymph nodes were stimulated with HDM for 
5 days. Cell-free supernatant was used to assess cytokine production using ELISA. E, 
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Expression of mast cell proteases was determined by quantitative PCR analysis of lung 
RNA. F, Mast cell numbers were evaluated in tracheal sections. Data shown represent mean 
± SEM of 5 to 7 mice per group from 2 independent experiments with similar results. *P < 
0.05. G, Immunohistochemical staining of T cells (CD3) and mast cells (c-kit, CD117) with 
Vulcan Red and DAB in paraffin embedded tracheal tissue sections. Green arrowhead 
indicates T cells and black arrow shows mast cells. Boxes on low magnification 
micrographs indicate the region for the higher magnification panel.
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Figure 4. 
T cell-dependent mast cell accumulation in HDM-induced chronic allergic airway 
inflammation. A, Numbers of inflammatory cells in the BAL fluid of wild-type, Sfpi1lck−/−, 
Rag1−/−, and unchallenged wild-type mice (UC) were determined. B and C, Mast cell 
infiltration in tracheal toluidine blue stained sections. Original magnification is indicated. 
Mast cell numbers were determined by counting in at least 5 hpfs. Boxes on low 
magnification micrographs indicate the region for the higher magnification panel. D, Serum 
mMCP-1 levels were determined by ELISA. Data are mean ± SEM of 5–7 mice per group 
and representative of 2 independent experiments with similar results. *P <0.05.
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